AbbVie

Proud to announce we've received a top score on this year's Inclusion Index from Seramount for fostering a workplace culture that encourages diversity, inclusion and employee growth. Read more: https://bit.ly/46QrHCt #BelongAtAbbVie #InclusionIndex2024

JUST IN: The European Commission has granted conditional marketing authorization in relapsed/refractory follicular #lymphoma, a form of #BloodCancer, after two or more lines of prior therapy, developed in collaboration with Genmab. Read more: https://bit.ly/3AyFvWb [Video description: On-screen text reads, “Oncology News.”]

Join us in congratulating Tim Richmond, our executive vice president and chief human resources officer, on receiving the HR Division - Academy of Management's 2024 "Distinguished HR Executive Award" for his #leadership in advancing the #HumanResources management field. This award highlights Tim’s contributions to the HR practice, including his ongoing support of HR research and education. As a member of our executive leadership team, Tim and the HR team he leads enable our growth and help make us one of the world’s best workplaces.

Earlier this year, our employees across the globe participated in AbbVie In Motion, our annual team-based movement and activity challenge. See how we make employee health and well-being one of our top priorities: https://bit.ly/3yzcby5 #AbbVieLife [Video description: Images and statistics recapping the impact of AbbVie in Motion around the world, including 16K participants; 1,400 teams from 69 countries; more than 25M total physical activity minutes logged.]

Thank you to our 13,000 employees who served their local #communities during Week of Possibilities, the AbbVie Foundation’s annual #volunteer event. Together they spent nearly 50,000 hours contributing to numerous community projects around the globe, including renovating and improving schools, serving meals, building homes, cleaning up waterways and more. See the full impact of their volunteering: https://bit.ly/4dyXFoQ #AbbVieGivesBack [Video description: Interviews with AbbVie employees talking about volunteering during Week of Possibilities and footage of volunteer activities.]

How long does it take to bring new #treatments from discovery, to clinical development, and then to patients? The answer: an average of 10-15 years. That’s why we’re challenging conventional timelines to cut that process in half. Learn more: https://bit.ly/3yhUNOq

NEWS: American Society of Hematology's journal, Blood, published updated results from a Phase 3 study, which includes six-year follow-up data in #patients with previously untreated chronic lymphocytic leukemia (#CLL). Learn more about the findings: https://bit.ly/3LPPUPB [Video description: On-screen text reads, “Oncology News.”]

To celebrate our #interns' great work this summer, we hosted a picnic on National Intern Day at our North Chicago HQ. Explore our #internship opportunities and see why we were named to WayUp and Yello.co's list of Top 100 Internship Programs of 2024: https://bit.ly/3WNax5i #AbbVieLife [Video description: Six AbbVie interns jumping over the video frame to transition from their workspace to an outdoor picnic.]

Cerevel Therapeutics is now part of AbbVie. Learn how this #acquisition strengthens our #neuroscience pipeline, continuing our mission to transform standards of care across neurological and psychiatric conditions. Explore: https://abbv.ie/53b6c2 $ABBV [Image description: On-screen text reads, "Cerevel is now part of AbbVie. Completion of acquisition adds pipeline of assets to complement our neuroscience portfolio. Click the link to learn more."]

We’re striving to make a difference for people impacted by #IBD. Learn how we’re working to reimagine the standards of care through innovation and research: https://abbv.ie/cb1af7 #UlcerativeColitis #CrohnsDisease [Image description: Roopal Thakkar, M.D., EVP, R&D, Chief Scientific Officer, AbbVie, says, "We are committed to strengthening our diversified inflammatory bowel disease (IBD) portfolio, providing healthcare professionals with more options to treat their IBD patients."]